BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/18/2023 7:44:15 AM | Browse: 177 | Download: 664
 |
Received |
|
2023-08-30 11:27 |
|
Peer-Review Started |
|
2023-08-30 11:30 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-09-29 02:54 |
|
Revised |
|
2023-10-16 15:07 |
|
Second Decision |
|
2023-10-23 01:05 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-10-26 07:22 |
|
Articles in Press |
|
2023-10-26 07:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-12-13 14:32 |
|
Publish the Manuscript Online |
|
2023-12-18 07:44 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Prospective Study |
| Article Title |
Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Adam Diamond, Sunil Karhadkar, Kenneth Chavin, Serban Constantinescu, Kwan N. Lau, Oscar Perez-Leal, Kerry Mohrien, Nicole Sifontis and Antonio Di Carlo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sunil Karhadkar, FACS, MCh, MD, Associate Professor, Department of Surgery, Temple University Hospital, No. 3401 North Broad Street, Philadelphia, PA 19140, United States. sunilk@temple.edu |
| Key Words |
Immunosuppression; Kidney transplant; Dosing; Tacrolimus; Therapeutic drug monitoring; Genotype |
| Core Tip |
In this single-arm, prospective, observational study we study once-daily, extended release tacrolimus dosing. Here we find that the expression of the cyctrochrome P450 enzyme, CYP3A5, is an important clinical factor to determine optimal dosage requirements after kidney transplantation. In kidney transplant recipients who express CYP3A5 activity, higher doses of extended-release tacrolimus are required to attain therapeutic trough concentrations. Delays in achieving therapeutic trough concentrations has been linked to increase rates of acute rejection which highlights the importance of this research in identifying dosing considerations for extended-release tacrolimus in the de novo kidney transplant setting. |
| Publish Date |
2023-12-18 07:44 |
| Citation |
Diamond A, Karhadkar S, Chavin K, Constantinescu S, Lau KN, Perez-Leal O, Mohrien K, Sifontis N, Di Carlo A. Dosing strategies for de novo once-daily extended release tacrolimus in kidney transplant recipients based on CYP3A5 genotype. World J Transplant 2023; 13(6): 368-378 |
| URL |
https://www.wjgnet.com/2220-3230/full/v13/i6/368.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v13.i6.368 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
